4 Healthcare Stock Stories To Kick Off the Trading Week

Varian Medical Systems (NYSE:VAR): Current price $66.97

Varian and Paul Scherrer Institute will work jointly to move forward motion management techniques for proton therapy. The multi-year accord, targeting the optimization of treatment strategies for indications such as cancers in the lung, liver, pancreas and breast, will study strategies employing a 4-D treatment planning simulator developed by the Institute. Proton therapy involves the use of a controlled beam of protons to target tumors with higher levels of precision than would be possible with other types of radiation therapy, potentially limiting damage to healthy surrounding tissue.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

var

Isis Pharmaceuticals (NASDAQ:ISIS): Current price $21.75

On Friday, analyst Jim Birchenough at BMO Capital Markets reiterated an Outperform on Isis shares and also elevated his price target from $22 to $31. In a report, Birchenough commented that  “The BMO Capital Markets US biotechnology team hosted a meeting this week with Isis Pharmaceuticals SVP of Clinical Development Dr. Richard Geary. Focus of the meeting was on a burgeoning pipeline of antisense oligonucleotide  therapeutics following recent approval of its first ASO therapeutic Kynamro. With 28 different ASO therapeutics in development, primary focus was on key late stage programs including wholly owned ISISApoC3-Rx for severe triglyceride elevation as well as partnered programs for ISIS-SMN-Rx for spinal muscular atrophy and TTR associated familial amyloid polyneuropathy.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

isis

Henry Schein (NASDAQ: HSIC): Current price $90.99

The world’s number-one provider of healthcare products and services to office-based dental, medical and animal health practitioners, announced that it has entered into a facility agreement of as much as $300 million with The Bank of Tokyo-Mitsubishi UFJ based on the collateral of its accounts receivable. The facility is committed and has a maturity of three years; Henry Schein intends to use it for working capital and general corporate purposes, including, but not limited to, capital expenditures, the buyback of capital stock and permitted refinancing of existing debt, along with the funding of potential acquisitions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

hsic

BioTime (NYSE: BTX): Current price $3.54

BioTime has reached an exclusive license agreement with the University of California, Los Angeles for novel tech connected with the treatment of stroke. The licensed technology was developed in the laboratories of Tom Carmichael, MD, PhD of the University’s Department of Neurology, at the David Geffen School of Medicine, and employs one of BioTime’s HyStem hydrogels to deliver locally released growth factors to improve recovery from stroke. Pre-clinical studies have shown that the localized delivery of growth factors like brain-derived neurotrophic factor results in a statistically significant improvement in post-stroke motor function in a murine model of ischemic stroke.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

btx

Don’t Miss: Here’s Why the U.S. Economy is Missing February.

More Articles About:    

More from The Cheat Sheet